Empowering AIDD - Building a Faster and Smarter Platform for Cancer Drug Discovery w/ Live Q&A

The next leap in oncology therapeutics demands speed, precision, and rapid molecular innovation — and AI-driven antibody design (AIDD) is beginning to deliver. In this talk, we will unveil how our platform leverages artificial intelligence to generate high-purity, diverse antibody-like libraries at unprecedented speed, feeding iterative design loops that accelerate hit-to-lead timelines. We’ll highlight recent platform enhancements, including AI-driven codon optimization and signal peptide selection, which — combined with our upcoming TurboCHO 3.0 expression system — are boosting yields and functional diversity. Two compelling case studies ground our approach: First, we tackle the notorious challenges of VHH (nanobody) library production — instability, aggregation, low expression — and reveal how AI-guided design and expression tuning overcome these hurdles. Second, we explore asymmetric bispecific antibodies, engineered to simultaneously engage tumor antigens and immune cells, and demonstrate their growing relevance in solid and hematologic cancers. Our upgraded platform aims to support the exploration of novel scaffolds and designing next-gen multispecifics, for smarter, faster, more effective cancer drug discovery.

Learning Objectives:

1. Next-Gen platforms are required to deliver on AI-accelerated antibody drug discovery.

2. How closed-loop optimization with real-time feedback can be achieved.

3. Mitigating late-stage risks early.